Rising to a Global Challenge

As a growing cause of death and morbidity among older adults worldwide, neurological diseases such as Alzheimer’s and dementia are creating unprecedented challenges across health care. Heterogeneous in nature and presenting with a wide variety of symptoms, these highly complex diseases carry unique diagnostic challenges and limitations.1


At Beckman Coulter, we believe blood-based neurologic disease biomarkers will forever change how diseases are investigated, diagnosed, and monitored. From disease diagnosis and prognosis to enabling drug discovery and development, the opportunities for accessible and scalable diagnostic testing for neurodegenerative diseases are enabling clinicians and laboratory staff to reimagine the standard of patient care.

Neurological disease prevalence by the numbers

neuro_infographic_rev

Fueled by epidemiological factors such as population growth, longer life expectancies, and the availability of novel therapeutics, we are facing a population that requires scalable, affordable, and easy-to-use testing in the core laboratory. We anticipate an unprecedented demand for reliable, highly sensitive blood-based testing for neurological diseases and beyond.



 

 

“We are investing in our immunoassay technology to develop new, blood-based, high throughput, high sensitivity assays to detect and measure neurological biomarkers at a scale to address the growing global challenge."
Kevin O'Reilly
President, Beckman Coulter Diagnostics


 

Improving Access through Scalability

At Beckman Coulter, we are committing to advance neurological patient care to make it more accessible to people around the world. With 90 years of diagnostic innovation and our legacy in workflow efficiency, reliability, and scalability, we are advancing the future of neurological disease diagnostics. Today, our solutions run over 1 million tests per hour, impacting over 1.2 billion patients per year around the world, and our biomarkers are unlocking more clinical insights than ever before, providing meaningful, actionable data.

Blood-based Neurology Disease Assays

Research Use Only Assays
p-Tau217
β-Amyloid 1-42
GFAP
NfL
APOE ε4

Assays in Development.
For Research Use Only. Not for use in diagnostic procedures.

 

High Sensitivity Immunoassay Testing

Revolutionize your core lab’s impact with unprecedented sensitivity to meet the needs of today and tomorrow

Infectious Disease Blood Virus

Our infectious disease assays boost confidence in accurate reporting and timely disease management

Partnering to Improve Patient Outcomes. Together, we can make a difference. Request more information.


References:

1. Erkkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2078;70(4):a033778. Published 2018 Apr 2. doi:70.1101/cshperspect.a033118

2. New study predicts the number of people living with Alzheimer’s disease to triple by 2050. Alzheimer’s Disease International. 2022. Accessed April 30, 2024. https://www.alzint.org/news-events/news/new-data-predicts-the-number-of-people-living-with-alzheimers-disease-to-triple-by-2050/

3. Parkinson disease. World Health Organization. 2023. Accessed April 30, 2024.
https://www.who.int/news-room/fact-sheets/detail/parkinson-disease#:~:text=The%20prevalence%20of%20PD%20has%20doubled%20in,5.8%20million%20disability%20adjusted%20life%20years%20

4. GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. (2019). Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, 18(1), 56–87. doi: 10.1016/S1474-4422(18)30415-0

5. Dewan, M. C., Rattani, A., Gupta, S., Baticulon, R. E., Hung, Y.-C., Punchak, M., … Park, K. B. (2018). Estimating the global incidence of traumatic brain injury. Journal of Neurosurgery, 130(4), 1080–1097. doi: 10.3171/2017.10.JNS17352

6. Multiple sclerosis. World Health Organization. 2023. Accessed April 30, 2024.
https://www.who.int/news-room/fact-sheets/detail/multiple-sclerosis#:~:text=It%20is%20estimated%20that%20over,young%20adults%20and%20in%20females

* Full name DxI 9000 Access Immunoassay Analyzer

2024-13623